Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dolutegravir vs Tivicay in Healthy Subjects
NCT06450275Phase 1Completed
- Sponsor
- Humanis
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Humanis. Primary endpoints: Maximum concentration obtained at 23 hours and AUC from time 0 to last collection time t at 23 hours. Started Jan 2024; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06450275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450275.